Search Results

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company, Radionetics Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the Crinetics’ Core Nonpeptide Platform and Includes Drug Candidates and Leads Against 10 Oncology Targets – Radionetics Frazier Healthcare Partners, today announced the formation of an independently operated new company, Radionetics Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the

heart failure drug following reverse merger with Avrobio Lilly signs $140M upfront partnership with Radionetics

Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.